<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35875995</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-7836</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of thrombosis and haemostasis : JTH</Title><ISOAbbreviation>J Thromb Haemost</ISOAbbreviation></Journal><ArticleTitle>Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction.</ArticleTitle><Pagination><StartPage>2429</StartPage><EndPage>2438</EndPage><MedlinePgn>2429-2438</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jth.15830</ELocationID><Abstract><AbstractText Label="BACKGROUND">Prolonged recovery is common after acute SARS-CoV-2 infection; however, the pathophysiological mechanisms underpinning Long COVID syndrome remain unknown. VWF/ADAMTS-13 imbalance, dysregulated angiogenesis, and immunothrombosis are hallmarks of acute COVID-19. We hypothesized that VWF/ADAMTS-13 imbalance persists in convalescence together with endothelial cell (EC) activation and angiogenic disturbance. Additionally, we postulate that ongoing immune cell dysfunction may be linked to sustained EC and coagulation activation.</AbstractText><AbstractText Label="PATIENTS AND METHODS">Fifty patients were reviewed at a minimum of 6&#x2009;weeks following acute COVID-19. ADAMTS-13, Weibel Palade Body (WPB) proteins, and angiogenesis-related proteins were assessed and clinical evaluation and immunophenotyping performed. Comparisons were made with healthy controls (n&#xa0;=&#xa0;20) and acute COVID-19 patients (n&#xa0;=&#xa0;36).</AbstractText><AbstractText Label="RESULTS">ADAMTS-13 levels were reduced (p&#xa0;=&#xa0;0.009) and the VWF-ADAMTS-13 ratio was increased in convalescence (p&#xa0;=&#xa0;0.0004). Levels of platelet factor 4 (PF4), a putative protector of VWF, were also elevated (p&#xa0;=&#xa0;0.0001). A non-significant increase in WPB proteins Angiopoietin-2 (Ang-2) and Osteoprotegerin (OPG) was observed in convalescent patients and WPB markers correlated with EC parameters. Enhanced expression of 21 angiogenesis-related proteins was observed in convalescent COVID-19. Finally, immunophenotyping revealed significantly elevated intermediate monocytes and activated CD4+ and CD8+ T cells in convalescence, which correlated with thrombin generation and endotheliopathy markers, respectively.</AbstractText><AbstractText Label="CONCLUSION">Our data provide insights into sustained EC activation, dysregulated angiogenesis, and VWF/ADAMTS-13 axis imbalance in convalescent COVID-19. In keeping with the pivotal role of immunothrombosis in acute COVID-19, our findings support the hypothesis that abnormal T cell and monocyte populations may be important in the context of persistent EC activation and hemostatic dysfunction during convalescence.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fogarty</LastName><ForeName>Helen</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8161-7931</Identifier><AffiliationInfo><Affiliation>Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Soracha E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0003-1730-8485</Identifier><AffiliationInfo><Affiliation>Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Townsend</LastName><ForeName>Liam</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7089-0665</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, School of Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karampini</LastName><ForeName>Ellie</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4082-076X</Identifier><AffiliationInfo><Affiliation>Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elliott</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6297-4308</Identifier><AffiliationInfo><Affiliation>Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conlon</LastName><ForeName>Niall</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1102-0758</Identifier><AffiliationInfo><Affiliation>Department of Clinical Medicine, School of Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunne</LastName><ForeName>Jean</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5816-3855</Identifier><AffiliationInfo><Affiliation>Department of Immunology, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiersey</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6434-0878</Identifier><AffiliationInfo><Affiliation>Department of Immunology, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naughton</LastName><ForeName>Aifric</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4557-1280</Identifier><AffiliationInfo><Affiliation>Department of Immunology, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gardiner</LastName><ForeName>Mary</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8541-148X</Identifier><AffiliationInfo><Affiliation>Department of Immunology, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Mary</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0214-1718</Identifier><AffiliationInfo><Affiliation>National Coagulation Centre, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergin</LastName><ForeName>Colm</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6651-1132</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, School of Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Sullivan</LastName><ForeName>Jamie M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-1162-8739</Identifier><AffiliationInfo><Affiliation>Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin-Loeches</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-5834-4063</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadarajan</LastName><ForeName>Parthiban</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1685-1876</Identifier><AffiliationInfo><Affiliation>Department of Respiratory Medicine, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bannan</LastName><ForeName>Ciaran</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9288-8574</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallon</LastName><ForeName>Patrick W</ForeName><Initials>PW</Initials><Identifier Source="ORCID">0000-0002-4337-6222</Identifier><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research, University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St Vincent's University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curley</LastName><ForeName>Gerard F</ForeName><Initials>GF</Initials><Identifier Source="ORCID">0000-0003-0271-195X</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesia and Critical Care, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preston</LastName><ForeName>Roger J S</ForeName><Initials>RJS</Initials><Identifier Source="ORCID">0000-0003-0108-4077</Identifier><AffiliationInfo><Affiliation>Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rehill</LastName><ForeName>Aisling M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-2987-126X</Identifier><AffiliationInfo><Affiliation>Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Ross I</ForeName><Initials>RI</Initials><Identifier Source="ORCID">0000-0002-2728-6788</Identifier><AffiliationInfo><Affiliation>Western Australia Centre for Thrombosis and Haemostasis, Perth Blood Institute, Murdoch University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Irish-Australian Blood Collaborative (IABC) Network, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheallaigh</LastName><ForeName>Cliona Ni</ForeName><Initials>CN</Initials><Identifier Source="ORCID">0000-0002-0842-425X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, School of Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Donnell</LastName><ForeName>James S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0003-0309-3313</Identifier><AffiliationInfo><Affiliation>Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Coagulation Centre, St James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Irish-Australian Blood Collaborative (IABC) Network, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Irish COVID-19 Vasculopathy Study (iCVS) Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Thromb Haemost</MedlineTA><NlmUniqueID>101170508</NlmUniqueID><ISSNLinking>1538-7836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042702">Angiopoietin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006490">Hemostatics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053244">Osteoprotegerin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>37270-94-3</RegistryNumber><NameOfSubstance UI="D010978">Platelet Factor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.5</RegistryNumber><NameOfSubstance UI="D013917">Thrombin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.87</RegistryNumber><NameOfSubstance UI="D000071120">ADAMTS13 Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000071120" MajorTopicYN="N">ADAMTS13 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042702" MajorTopicYN="N">Angiopoietin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003289" MajorTopicYN="N">Convalescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006490" MajorTopicYN="Y">Hemostatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053244" MajorTopicYN="N">Osteoprotegerin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010978" MajorTopicYN="N">Platelet Factor 4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013917" MajorTopicYN="N">Thrombin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014841" MajorTopicYN="N">von Willebrand Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Weibel Palade body exocytosis</Keyword><Keyword MajorTopicYN="N">convalescent COVID-19</Keyword><Keyword MajorTopicYN="N">endothelial cell activation</Keyword><Keyword MajorTopicYN="N">immune dysfunction</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>J.S.O'D. has served on the speaker's bureau for Baxter, Bayer, Novo Nordisk, Sobi, Boehringer Ingelheim, Leo Pharma, Takeda, and Octapharma. He has also served on the advisory boards of Baxter, Sobi, Bayer, Octapharma CSL Behring, Daiichi Sankyo, Boehringer Ingelheim, Takeda, and Pfizer. J.S.O'D. has also received research grant funding awards from 3M, Baxter, Bayer, Pfizer, Shire, Takeda, and Novo Nordisk. The remaining authors have no conflicts of interest to declare.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>O'Connell</LastName><ForeName>Niamh</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kenny</LastName><ForeName>Dermot</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fazavana</LastName><ForeName>Judicael</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>25</Day><Hour>4</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35875995</ArticleId><ArticleId IdType="pmc">PMC9349977</ArticleId><ArticleId IdType="doi">10.1111/jth.15830</ArticleId><ArticleId IdType="pii">S1538-7836(22)19058-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nat Med. 2021;27(4):601&#x2010;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS&#x2010;CoV&#x2010;2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence . Clinical Guidelines. COVID&#x2010;19 Rapid Guideline: Managing the Long&#x2010;Term Effects of COVID&#x2010;19. National Institute for Health and Care Excellence (NICE). Copyright &#xa9; NICE 2020; 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>
Prevention CfDCa
. Post&#x2010;COVID conditions: information for healthcare providers; 2021. https://wwwcdcgov/coronavirus/2019&#x2010;ncov/hcp/clinical&#x2010;care/post&#x2010;covid&#x2010;conditionshtml
</Citation></Reference><Reference><Citation>Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID19 coagulopathy in Caucasian patients. Br J Haematol. 2020;189(6):1044&#x2010;1049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264579</ArticleId><ArticleId IdType="pubmed">32330308</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost. 2021;19(10):2546&#x2010;2553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Fogarty H, Dyer A, et al. Prolonged elevation of D&#x2010;dimer levels in convalescent COVID&#x2010;19 patients is independent of the acute phase response. J Thromb Haemost. 2021;19:1064&#x2010;1070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013297</ArticleId><ArticleId IdType="pubmed">33587810</ArticleId></ArticleIdList></Reference><Reference><Citation>von Meijenfeldt FA, Havervall S, Adelmeijer J, et al. Sustained prothrombotic changes in COVID&#x2010;19 patients 4 months after hospital discharge. Blood Adv. 2021;5(3):756&#x2010;759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857699</ArticleId><ArticleId IdType="pubmed">33560386</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan BE, Wong SW, Sum CLL, et al. Hypercoagulability, endotheliopathy, and inflammation approximating 1&#x2009;year after recovery: assessing the long&#x2010;term outcomes in COVID&#x2010;19 patients. Am J Hematol. 2022;97:915&#x2010;923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9073976</ArticleId><ArticleId IdType="pubmed">35477923</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID&#x2010;19. Lancet. 2020;395(10234):1417&#x2010;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid&#x2010;19. N Engl J Med. 2020;383(2):120&#x2010;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Sullivan JM, Mc Gonagle D, Ward SE, Preston RJ, O'Donnell JS. Endothelial cells orchestrate COVID&#x2010;19 coagulopathy. Lancet Haematol. 2020;7(8):e553&#x2010;e555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7326442</ArticleId><ArticleId IdType="pubmed">32619412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowenstein CJ, Solomon SD. Severe COVID&#x2010;19 is a microvascular disease. Circulation. 2020;142(17):1609&#x2010;1611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7580651</ArticleId><ArticleId IdType="pubmed">32877231</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donnell JS, Peyvandi F, Martin&#x2010;Loeches I. Pulmonary immuno&#x2010;thrombosis in COVID&#x2010;19 ARDS pathogenesis. Intensive Care Med. 2021;47(8):899&#x2010;902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8164686</ArticleId><ArticleId IdType="pubmed">34052905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward SE, Curley GF, Lavin M, et al. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID&#x2010;19): evidence of acute and sustained endothelial cell activation. Br J Haematol. 2020;192(4):714&#x2010;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">33326604</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippe A, Gendron N, Bory O, et al. Von Willebrand factor collagen&#x2010;binding capacity predicts in&#x2010;hospital mortality in COVID&#x2010;19 patients: insight from VWF/ADAMTS13 ratio imbalance. Angiogenesis. 2021;24(3):407&#x2010;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8111656</ArticleId><ArticleId IdType="pubmed">33974165</ArticleId></ArticleIdList></Reference><Reference><Citation>Villa E, Critelli R, Lasagni S, et al. Dynamic angiopoietin&#x2010;2 assessment predicts survival and chronic course in hospitalized patients with COVID&#x2010;19. Blood Adv. 2021;5(3):662&#x2010;673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7876870</ArticleId><ArticleId IdType="pubmed">33560382</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward SE, Fogarty H, Karampini E, et al. ADAMTS13 regulation of VWF multimer distribution in severe COVID&#x2010;19. J Thromb Haemost. 2021;19(8):1914&#x2010;1921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8237059</ArticleId><ArticleId IdType="pubmed">34053187</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancini I, Baronciani L, Artoni A, et al. The ADAMTS13&#x2010;von Willebrand factor axis in COVID&#x2010;19 patients. J Thromb Haemost. 2021;19(2):513&#x2010;521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753796</ArticleId><ArticleId IdType="pubmed">33230904</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguila S, Lavin M, Dalton N, et al. Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood. 2019;133(14):1585&#x2010;1596.</Citation><ArticleIdList><ArticleId IdType="pubmed">30770394</ArticleId></ArticleIdList></Reference><Reference><Citation>Harmon S, Preston RJ, Ni Ainle F, et al. Dissociation of activated protein C functions by elimination of protein S cofactor enhancement. J Biol Chem. 2008;283(45):30531&#x2010;30539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662146</ArticleId><ArticleId IdType="pubmed">18779332</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Naughton A, et al. Longitudinal analysis of COVID&#x2010;19 patients shows age&#x2010;associated T cell changes independent of ongoing ill&#x2010;health. Front Immunol. 2021;12:676932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8138306</ArticleId><ArticleId IdType="pubmed">34025675</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasannan N, Heightman M, Hillman T, et al. Impaired exercise capacity in post&#x2010;COVID syndrome: the role of VWF&#x2010;ADAMTS13 axis. Blood Adv. 2022;6:4041&#x2010;4048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9098525</ArticleId><ArticleId IdType="pubmed">35543533</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell&#x2010;derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104(1):100&#x2010;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">15026315</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazy I, Elliott TD, Arnold DM. Platelet factor 4 inhibits ADAMTS13 activity and regulates the multimeric distribution of von Willebrand factor. Br J Haematol. 2020;190(4):594&#x2010;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">32130721</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis. 2009;12(1):35&#x2010;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">19105036</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahbazi S, Lenting PJ, Fribourg C, Terraube V, Denis CV, Christophe OD. Characterization of the interaction between von Willebrand factor and osteoprotegerin. J Thromb Haemost. 2007;5(9):1956&#x2010;1962.</Citation><ArticleIdList><ArticleId IdType="pubmed">17723135</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie X, Qian L, Sun R, et al. Multi&#x2010;organ proteomic landscape of COVID&#x2010;19 autopsies. Cell. 2021;184(3):775&#x2010;791.e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7794601</ArticleId><ArticleId IdType="pubmed">33503446</ArticleId></ArticleIdList></Reference><Reference><Citation>Smadja DM, Philippe A, Bory O, et al. Placental growth factor level in plasma predicts COVID&#x2010;19 severity and in&#x2010;hospital mortality. J Thromb Haemost. 2021;19(7):1823&#x2010;1830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8250221</ArticleId><ArticleId IdType="pubmed">33830623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hottz ED, Azevedo&#x2010;Quintanilha IG, Palhinha L, et al. Platelet activation and platelet&#x2010;monocyte aggregate formation trigger tissue factor expression in patients with severe COVID&#x2010;19. Blood. 2020;136(11):1330&#x2010;1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7483437</ArticleId><ArticleId IdType="pubmed">32678428</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>